At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
01801 INNOVENT BIO
Market Closed 06-05 16:09:12
76.600
+0.200
+0.26%
High79.800Low76.100Vol15.10M
Open77.350D1 Closing76.400Amplitude4.84%
Mkt Cap133.13BTradable Cap133.13BTotal Shares1.74B
T/O1.17BT/O Rate0.87%Tradable Shares1.74B
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.
BUZZ-Innovent climbs most in a week on new drug application for gastric cancer
Reuters  ·  06-05 10:26
BUZZ-Innovent climbs most in a week on new drug application for gastric cancer
Movement Alert｜Innovent Biologics Rises 3.01% in Regular Trading, Global First CLDN18.2 ADC Drug Application Accepted for Gastric Cancer
Market Focus  ·  06-05 09:55
Movement Alert｜Innovent Biologics Rises 3.01% in Regular Trading, Global First CLDN18.2 ADC Drug Application Accepted for Gastric Cancer
Innovent Biologics Adds 10,000 Shares from Option Exercise; Issued Share Capital Reaches 1.74 Billion
Bulletin Express  ·  06-04 22:43
Innovent Biologics Adds 10,000 Shares from Option Exercise; Issued Share Capital Reaches 1.74 Billion
Innovent Biologics' Application for Gastric Cancer Drug Accepted in China
MT Newswires Live  ·  06-04 17:54
Innovent Biologics' Application for Gastric Cancer Drug Accepted in China
INNOVENT BIO Receives NMPA Priority Review for World’s First CLDN18.2 ADC Following Phase 3 Success
Bulletin Express  ·  06-04 16:48
INNOVENT BIO Receives NMPA Priority Review for World’s First CLDN18.2 ADC Following Phase 3 Success
Innovent Biologics Announces NMPA Acceptance of New Drug Application for IBI343 in Advanced Gastric Cancer
Stock News  ·  06-04 16:36
Innovent Biologics Announces NMPA Acceptance of New Drug Application for IBI343 in Advanced Gastric Cancer
World's First Cldn18.2 ADC for Regulatory Review: Innovent Biologics Announces Ibi343 (Arcotatug Tavatecan) Met Primary Endpoint in International Phase 3 Study in Advanced Refractory Gastric Cancer and Nda Accepted by China Nmpa
THOMSON REUTERS  ·  06-04 16:35
World's First Cldn18.2 ADC for Regulatory Review: Innovent Biologics Announces Ibi343 (Arcotatug Tavatecan) Met Primary Endpoint in International Phase 3 Study in Advanced Refractory Gastric Cancer and Nda Accepted by China Nmpa
BRIEF-Innovent Biologics Says NMPA Accepts NDA For IBI343 (Arcotatug Tavatecan)
Reuters  ·  06-04 16:31
BRIEF-Innovent Biologics Says NMPA Accepts NDA For IBI343 (Arcotatug Tavatecan)
Innovent says China regulator accepts IBI343 gastric cancer NDA for priority review
Reuters  ·  06-04 16:31
Innovent says China regulator accepts IBI343 gastric cancer NDA for priority review
Innovent Biologics - Nmpa Accepts Nda for Ibi343 (Arcotatug Tavatecan) for Advanced Gastric Cancer
THOMSON REUTERS  ·  06-04 16:30
Innovent Biologics - Nmpa Accepts Nda for Ibi343 (Arcotatug Tavatecan) for Advanced Gastric Cancer
Southwest Securities Highlights Innovent Biologics' Strategic Collaboration with Pfizer to Accelerate Oncology Drug Development
Stock News  ·  06-04 14:53
Southwest Securities Highlights Innovent Biologics' Strategic Collaboration with Pfizer to Accelerate Oncology Drug Development
Jiao Yin International Retains 'Buy' Stance on Innovent Bio, Sets Target at HK$105
Stock News  ·  06-03 14:40
Jiao Yin International Retains 'Buy' Stance on Innovent Bio, Sets Target at HK$105
Movement Alert｜Innovent Biologics Falls 3.04% in Regular Trading, Pfizer Deal Regulatory Uncertainty and Biotech Sector Selloff Weigh on Shares
Market Focus  ·  06-03 10:01
Movement Alert｜Innovent Biologics Falls 3.04% in Regular Trading, Pfizer Deal Regulatory Uncertainty and Biotech Sector Selloff Weigh on Shares
Stock Track | Innovent Biologics Plummets 5.01% Intraday on Pfizer Deal Regulatory Concerns and Biotech Sector Selloff
Stock Track  ·  06-02
Stock Track | Innovent Biologics Plummets 5.01% Intraday on Pfizer Deal Regulatory Concerns and Biotech Sector Selloff
Movement Alert｜Innovent Biologics Falls 3.15% in Regular Trading, Pfizer Deal Regulatory Uncertainty Compounds Biotech Sector Selloff
Market Focus  ·  06-02
Movement Alert｜Innovent Biologics Falls 3.15% in Regular Trading, Pfizer Deal Regulatory Uncertainty Compounds Biotech Sector Selloff
Movement Alert｜Innovent Biologics Falls 3.12% in Regular Trading, Biotech Sector Pullback Compounds Pfizer Deal Regulatory Uncertainty
Market Focus  ·  06-01
Movement Alert｜Innovent Biologics Falls 3.12% in Regular Trading, Biotech Sector Pullback Compounds Pfizer Deal Regulatory Uncertainty
2026 Asco | Innovent Presents Long-Term Follow-up Results From the Poc Study of Ibi363 (Tak-928) (Pd-1/Il-2Α-Bias Bispecific Fusion Protein), Showing Robust Survival Benefits in Advanced Immunotherapy-Resistant Non-Small Cell Lung Cancer
THOMSON REUTERS  ·  06-01
2026 Asco | Innovent Presents Long-Term Follow-up Results From the Poc Study of Ibi363 (Tak-928) (Pd-1/Il-2Α-Bias Bispecific Fusion Protein), Showing Robust Survival Benefits in Advanced Immunotherapy-Resistant Non-Small Cell Lung Cancer
Asian Market's May 2026 Stocks Priced Below Estimated Value
Simply Wall St.  ·  06-01
Asian Market's May 2026 Stocks Priced Below Estimated Value
Hong Kong Market Rises; LENOVO GROUP Surges to New Highs, Property and Biotech Stocks Shine
Stock News  ·  05-29
Hong Kong Market Rises; LENOVO GROUP Surges to New Highs, Property and Biotech Stocks Shine
Hong Kong Stocks Rebound on U.S.-Iran Truce Talks; Creality 3D Technology Jumps on Debut
MT Newswires Live  ·  05-29
Hong Kong Stocks Rebound on U.S.-Iran Truce Talks; Creality 3D Technology Jumps on Debut

Introduction

Company Name.
INNOVENT BIO
Affiliated Markets:
SEHK
Listing Date:
--
Main Business:
Innovent Biologics Inc is an investment holding company principally engaged in the research, development, production and sales of innovative medicines for the treatment of diseases such as cancer, cardiovascular and metabolic (CVM), autoimmune and eye diseases. The pipeline covering monoclonal antibodies, multi-specific antibodies, immuno-cytokine, antibody-drug conjugates (ADCs), cell therapy and small molecules. The Company’s main products include TYVYT (sintilimab injection), BYVASDA (bevacizumab injection), SULINNO (adalimumab injection), HALPRYZA (rituximab injection), Pemazyre (pemigatinib) and others. The Company mainly conducts its businesses within domestic and overseas markets.
Issue price:
--